Buttler, Kerstin

[["dc.bibliographiccitation.firstpage","220"],["dc.bibliographiccitation.lastpage","229"],["dc.contributor.author","Wilting, Jörg"],["dc.contributor.author","Buttler, Kerstin"],["dc.contributor.author","Rössler, Jochen"],["dc.contributor.author","Norgall, Susanne"],["dc.contributor.author","Schweigerer, Lothar"],["dc.contributor.author","Weich, Herbert A."],["dc.contributor.author","Papoutsi, Maria"],["dc.contributor.editor","Chadwick, Derek J."],["dc.contributor.editor","Goode, Jamie"],["dc.date.accessioned","2021-06-02T10:44:30Z"],["dc.date.available","2021-06-02T10:44:30Z"],["dc.date.issued","2007"],["dc.identifier.doi","10.1002/9780470319413.ch17"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/87064"],["dc.notes.intern","DOI-Import GROB-425"],["dc.publisher","John Wiley & Sons, Ltd"],["dc.publisher.place","Chichester, UK"],["dc.relation.eisbn","978-0-470-31941-3"],["dc.relation.isbn","978-0-470-03428-6"],["dc.relation.ispartof","Vascular Development"],["dc.title","Embryonic Development and Malformation of Lymphatic Vessels"],["dc.type","book_chapter"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2952"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Developmental Dynamics"],["dc.bibliographiccitation.lastpage","2961"],["dc.bibliographiccitation.volume","236"],["dc.contributor.author","Kasten, Philipp"],["dc.contributor.author","Schnoeink, Gerrit"],["dc.contributor.author","Bergmann, Astrid"],["dc.contributor.author","Papoutsi, Maria"],["dc.contributor.author","Buttler, Kerstin"],["dc.contributor.author","Roessler, Jochen"],["dc.contributor.author","Weich, Herbert A."],["dc.contributor.author","Wilting, Joerg"],["dc.date.accessioned","2018-11-07T10:57:58Z"],["dc.date.available","2018-11-07T10:57:58Z"],["dc.date.issued","2007"],["dc.description.abstract","Lymphangioma is a disfiguring malformation of early childhood. A mouse lymphangioma model has been established by injecting Freund's incomplete adjuvant (FIA) intraperitoneally, but has not been compared with the human disease. We show that, in accordance with studies from the 1960s, the mouse model represents an oil-granuloma, made up of CD45-positive leukocytes and invaded by blood and lymph vessels. Several markers of lymphatic endothelial cells are expressed in both mouse and human, like CD31, Prox1, podoplanin, and Lyve-1. However, the human disease affects all parts of the lymphovascular tree. We observed convolutes of lymphatic capillaries, irregularly formed collectors with signs of disintegration, and large lymph cysts. We observed VEGFR-2 and -3 expression in both blood vessels and lymphatics of the patients, whereas in mouse VEGFR-2 was confined to activated blood vessels. The experimental mouse FIA model represents a vascularized oil-granuloma rather than a lymphangioma and reflects the complexity of human lymphangioma only partially."],["dc.description.sponsorship","NICHD NIH HHS [N01-HD-6-2915]"],["dc.identifier.doi","10.1002/dvdy.21298"],["dc.identifier.isi","000250192100025"],["dc.identifier.pmid","17879316"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/50377"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-liss"],["dc.relation.issn","1058-8388"],["dc.title","Similarities and differences of human and experimental mouse lymphangiomas"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","761"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Angiogenesis"],["dc.bibliographiccitation.lastpage","762"],["dc.bibliographiccitation.volume","17"],["dc.contributor.author","Buttler, Kerstin"],["dc.contributor.author","Badar, Muhammad"],["dc.contributor.author","Seiffart, V."],["dc.contributor.author","Laggies, Sandra"],["dc.contributor.author","Gross, G."],["dc.contributor.author","Weich, Herbert A."],["dc.contributor.author","Wilting, J."],["dc.date.accessioned","2018-11-07T09:38:16Z"],["dc.date.available","2018-11-07T09:38:16Z"],["dc.date.issued","2014"],["dc.identifier.isi","000338213400154"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33034"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Dordrecht"],["dc.relation.issn","1573-7209"],["dc.relation.issn","0969-6970"],["dc.title","De novo hem- and lymphangiogenesis by endothelial progenitor and mesenchymal stem cells in immunocompetent mice"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1513"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","Cellular and Molecular Life Sciences"],["dc.bibliographiccitation.lastpage","1527"],["dc.bibliographiccitation.volume","71"],["dc.contributor.author","Buttler, Kerstin"],["dc.contributor.author","Badar, Muhammad"],["dc.contributor.author","Seiffart, Virginia"],["dc.contributor.author","Laggies, Sandra"],["dc.contributor.author","Gross, Gerhard"],["dc.contributor.author","Wilting, Joerg"],["dc.contributor.author","Weich, Herbert A."],["dc.date.accessioned","2018-11-07T09:42:13Z"],["dc.date.available","2018-11-07T09:42:13Z"],["dc.date.issued","2014"],["dc.description.abstract","Cellular pro-angiogenic therapies may be applicable for the treatment of peripheral vascular diseases. Interactions between mesenchymal stem cells (MSCs) and endothelial progenitor cells (EPCs) may provide such a treatment option. With the exception of some studies in man, experiments have only been performed in immunodeficient mice and rats. We studied an immunocompetent syngeneic mouse model. We isolated MSCs from bone marrow and EPCs from the lung of adult C57/Bl.6 mice and co-injected them in Matrigel subcutaneously in adult C57/Bl.6 mice. We demonstrate development of both blood vessels and lymphatics. Grafted EPCs integrated into the lining of the two vessel types, whereas MSCs usually did not incorporate into the vessel wall. Injections of each separate cell type did not, or hardly, reveal de novo angiogenesis. The release of VEGF-A by MSCs has been shown before, but its inhibitors, e.g., soluble VEGF receptors, have not been studied. We performed qualitative and quantitative studies of the proteins released by EPCs, MSCs, and cocultures of the cells. Despite the secretion of VEGF inhibitors (sVEGFR-1, sVEGFR-2) by EPCs, VEGF-A was secreted by MSCs at bioavailable amounts (350 pg/ml). We confirm the secretion of PlGF, FGF-1, MCP-1, and PDGFs by EPCs/MSCs and suggest functions for VEGF-B, amphiregulin, fractalkine, CXCL10, and CXCL16 during MSC-induced hem- and lymphangiogenesis. We assume that lymphangiogenesis is induced indirectly by growth factors from immigrating leukocytes, which we found in close association with the lymphatic networks. Inflammatory responses to the cellular markers GFP and cell-tracker red (CMPTX) used for tracing of EPCs or MSCs were not observed. Our studies demonstrate the feasibility of pro-angiogenic/lymphangiogenic therapies in immunocompetent animals and indicate new MSC/EPC-derived angiogenic factors."],["dc.identifier.doi","10.1007/s00018-013-1460-8"],["dc.identifier.isi","000333125800012"],["dc.identifier.pmid","23995988"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33906"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Basel"],["dc.relation.issn","1420-9071"],["dc.relation.issn","1420-682X"],["dc.title","De novo hem- and lymphangiogenesis by endothelial progenitor and mesenchymal stem cells in immunocompetent mice"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]